Study: Single Dose of Vaccine May Protect Older Adults from RSV-Related Infection
Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.
Convenience, Effectiveness Prove Significant Attributes in Vaccine Uptake Decisions
US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.
